Research
Measuring Carbon Monoxide as a Clinical Tool in Cystic Fibrosis
Exhaled Carbon Monoxide as a Clinical Tool in Cystic Fibrosis (CF)
Protocol Description
The purpose of this Phase II study is to examine the relationship between exhaled carbon monoxide and other tests of lung disease in cystic fibrosis patients. Specifically it explores the use of various breathing tests to objectively quantify dyspnea, or difficulty breathing, in people with cystic fibrosis. Levels of exhaled carbon monoxide could possibly indicate a worsening of lung disease and may, over time, be even better than conventional pulmonary function tests for showing the severity of lung disease. Such tests may also help to point out patients most at risk for rapid declines in lung function.
Eligibility Criteria
Males and females, ages 6 and up, with cystic fibrosis who are being treated for a worsening lung infection will be asked to participate in this research study.
Males: At least age 6
Females: At least age 6
Requirements
Through a series of 3 visits, patients will be given breathing tests, with heart rate and oxygen saturation measured during exercise. Measurements will be taken before treatment for a lung infection, after completion of treatment and in a follow-up visit, 2 to 6 weeks later.
Visits: 3
Duration: Approximately 2 to 3 months
Status: Open for Enrollment
Source of Support
Cystic Fibrosis Foundation
Primary Investigator(s)
Joseph Pilewski, MD
Contact Information
To get started, please contact:
Elizabeth Hartigan, MPH, RN, CCRC
1-877-296-9026
